Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma

World Journal of Surgical Oncology

Chang-Fu Zhou¹  Shui-Yuan Liu¹  Jian-Dong Zhang¹  Zhi-Xiong Lin¹  Guo-Shi Lin¹  Chen-Xing Wu² 

[1] Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, 20 Cazhong Road, Fuzhou 350005, Fujian, China;Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China

关键词: MRI;    Necrosis;    Peritumoral edema;    Prognosis;    Glioblastoma;   

Others  :  1137174
DOI  :  10.1186/s12957-015-0496-7

 received in 2014-11-19, accepted in 2015-02-01,  发布年份 2015

【 摘 要 】

Background

Magnetic resonance imaging (MRI) plays an irreplaceable role in the preoperative diagnosis of glioma, and its imaging features are the base of making treatment decisions in patients with glioma, but it is still controversial whether peritumoral edema shown by MRI from preoperative routine scans are associated with patient survival. The aim of this study was to assess the prognostic value of preoperative MRI features in patients with glioblastoma.

Methods

A retrospective review of 87 patients with newly diagnosed supratentorial glioblastoma was performed using medical records and MRI data from routine scans. The Kaplan-Meier method and COX proportional hazard model were applied to evaluate the prognostic impact on overall survival of pretreatment MRI features (including peritumoral edema, edema shape, necrosis, cyst, enhancement, tumor crosses midline, edema crosses midline, and tumor size).

Results

In addition to patient age, Karnofsky performance status (KPS) and postoperative chemoradiotherapy, peritumoral edema extent and necrosis on preoperative MRI were independent prognostic indicator for poor survival. Furthermore, patients with two unfavorable conditions (major edema and necrosis) had a shorter overall survival compared with the remainder.

Conclusions

Our data confirm that peritumoral edema extent and necrosis are helpful for predicting poor clinical outcome in glioblastoma. These features were easy to determine from routine MRI scans postoperatively and therefore could provide a certain instructive significance for clinical activities.

【 授权许可】

   
2015 Wu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 2007(114):97-109.
• [2]Central Brain Tumor Registry of the United States: CBTRUS statistical report: primary brain and central nervous system tumors in the United States in 2004–2006. Central Brain Tumor Registry of the United States, Hinsdale, Ill; 2010.
• [3]Yang LJ, Zhou CF, Lin ZX: Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer Invest. 2014, 32:31-6.
• [4]Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol. 2003, 30:10-4.
• [5]Dahlrot RH: The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J 2014, 61(10):B4944.
• [6]Schoenegger K, Oberndorfer S, Wuschitz B, Struhal W, Hainfellner J, Prayer D, et al.: Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol. 2009, 16:874-8.
• [7]Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al.: A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci. 2011, 18:66-70.
• [8]Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al.: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15:1100-8.
• [9]Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE: Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996, 27:65-73.
• [10]Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF: MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005, 26:2466-74.
• [11]Maldaun MV, Suki D, Lang FF, Prabhu S, Shi W, Fuller GN, et al.: Cystic glioblastoma multiforme: survival outcomes in 22 cases. J Neurosurg. 2004, 100:61-7.
• [12]Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al.: Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol. 2012, 7:1349-55.
• [13]Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK, et al.: A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg. 2011, 115:754-9.
• [14]Pierallini A, Bonamini M, Osti MF, Pantano P, Palmeggiani F, Santoro A, et al.: Supratentorial glioblastoma: neuroradiological findings and survival after surgery and radiotherapy. Neuroradiology. 1996, 38(Suppl 1):S26-30.
• [15]Liu SY, Mei WZ, Lin ZX: Pre-operative peritumoral edema and survival rate in glioblastoma multiforme. Onkologie. 2013, 36:679-84.
• [16]Lin ZX: Glioma-related edema: new insight into molecular mechanisms and their clinical implications. Chin J Cancer. 2013, 32:49-52.
• [17]Bonavia R, Inda MM, Cavenee WK, Furnari FB: Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011, 12:4055-60.
• [18]Hartmann M, Jansen O, Egelhof T, Forsting M, Albert FK, Sartor K: Effect of brain edema on the recurrence pattern of malignant gliomas. Radiologe. 1998, 38:948-53.
• [19]Seidel C, Dorner N, Osswald M, Wick A, Platten M, Bendszus M, et al.: Does age matter? A MRI study on peritumoral edema in newly diagnosed primary glioblastoma. BMC Cancer. 2011, 11:127. BioMed Central Full Text
• [20]Silbergeld DL, Rostomily RC, Alvord EC Jr: The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol. 1991, 10:179-85.
• [21]Yamahara T, Numa Y, Oishi T, Kawaguchi T, Seno T, Asai A, et al.: Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathol. 2010, 27:81-7.
• [22]Ruiz-Ontanon P, Orgaz JL, Aldaz B, Elosegui-Artola A, Martino J, Berciano MT, et al.: Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells. 2013, 31:1075-85.
• [23]Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, Hu SJ: Targeting role of glioma stem cells for glioblastoma multiforme. Curr Med Chem. 2013, 20:1974-84.
• [24]Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al.: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012, 488:522-6.
• [25]Mangiola A, de Bonis P, Maira G, Balducci M, Sica G, Lama G, et al.: Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer. 2008, 113:841-6.
• [26]Ito U, Reulen HJ, Tomita H, Ikeda J, Saito J, Maehara T: A computed tomography study on formation, propagation and resolution of edema fluid in metastatic brain tumors. Adv Neurol. 1990, 52:459-68.
• [27]Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95:190-8.
• [28]Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, et al.: MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma dataset. Radiology. 2013, 267:560-9.
• [29]D’Angelo MG, Afanasieva T, Aguzzi A: Angiogenesis in transgenic modelsof multistep carcinogenesis. J Neurooncol. 2000, 50:89-98.
• [30]Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat gliomamodel of tumor angiogenesis. Cancer Res. 1993, 53:5822-7.
• [31]Pierallini A, Bonamini M, Pantano P, Palmeggiani F, Raguso M, Osti MF, et al.: Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology. 1998, 40:150-3.
• [32]Rong Y, Durden DL, Van Meir EG, Brat DJ: 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006, 65:529-39.
• [33]Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, et al.: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004, 64:920-7.
• [34]Huang XD, Wang ZF, Dai LM, Li ZQ: Microarray analysis of the hypoxia-induced gene expression profile in malignant C6 glioma cells. Asian Pac J Cancer Prev. 2012, 13:4793-9.
• [35]Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM: Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol. 2009, 2:263-84.
• [36]Jyothirmayi R, Madhavan J, Nair MK, Rajan B: Conservative surgery and radiotherapy in the treatment of spinal cord astrocytoma. J Neurooncol. 1997, 33:205-11.
• [37]Shibamoto Y, Kitakabu Y, Takahashi M, Yamashita J, Oda Y, Kikuchi H, et al.: Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 1993, 72:190-5.
• [38]Adn M, Saikali S, Guegan Y, Hamlat A: Pathophysiology of glioma cyst formation. Med Hypotheses. 2006, 66:801-4.
• [39]Utsuki S, Oka H, Suzuki S, Shimizu S, Tanizaki Y, Kondo K, et al.: Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol. 2006, 23:29-34.
• [40]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96.